Business Daily Media

Men's Weekly

.

CK Life Sciences Files Patent Applications for Circular mRNA TROP2 Cancer Vaccine

Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth Inhibition

HONG KONG SAR - Media OutReach Newswire - 11 April 2025 - CK Life Sciences Int'l., (Holdings) Inc.

("CK Life Sciences"), a leader in cancer vaccine development, announces the latest progress in its pharmaceutical R&D, namely the filing of an Original Grant Patent application in Hong Kong and a provisional patent application in the United States for novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 ("TROP2").

TROP2 is a cell surface glycoprotein that is overexpressed in a wide range of cancers, including breast, lung, pancreatic, and colorectal cancers. This protein plays a critical role in cell proliferation, migration, and invasion, and its overexpression is frequently linked to aggressive tumor behavior and poor clinical outcomes. Given its high expression in cancer cells and minimal presence in normal tissues, TROP2 has emerged as a promising therapeutic target in oncology.

TROP2-positive triple-negative breast cancer animal study demonstrated 100% tumor growth inhibition

TROP2 cancer vaccines covered by the patent application include innovative circular mRNA (circRNA) and fusion protein vaccine constructs that can induce robust T cell immune responses and have demonstrated impressive tumor growth inhibition in preclinical studies of triple-negative breast cancer and colorectal cancer. The results of animal studies involving triple-negative breast cancer ("TNBC") have been encouraging, with mouse models showing 100% tumor growth inhibition after receiving the TROP2 cancer vaccine. Overall, 100% inhibition of tumor growth was achieved in four of the five studies when mice were treated with a TROP2 vaccine candidate, while the remaining study demonstrated approximately 80% tumor growth inhibition.

Triple-negative breast cancer disproportionately prevalent and aggressive among Asian women

The results of animal studies of the TROP2 cancer vaccines are of particular relevance to the Asian region. Breast cancer rates in Asia are rising sharply, with younger women widely affected. In particular, TNBC shows both higher prevalence and more aggressive behavior in Asian populations compared to Western counterparts. Additionally, TNBC has fewer treatment options and demonstrates significantly higher rates of metastasis and recurrence than other breast cancer subtypes.

Unprecedented anti-cancer efficacy

"TROP2 is an exciting therapeutic target and preclinical studies of our cancer vaccine in triple-negative breast cancer exhibited 100% inhibition of tumor growth, demonstrating unprecedented anti-cancer efficacy. We look forward to advancing our TROP2 cancer vaccine expeditiously into clinical trials to benefit patients and believe it holds significant potential in preventing cancer recurrence," said Dr. Melvin Toh, Chief Scientific Officer at CK Life Sciences.

Data on the TROP2 cancer vaccines will be presented at upcoming cancer conferences. In recent years, CK Life Sciences has showcased its growing early-stage cancer vaccine pipeline through preclinical data presentations at leading oncology conferences, alongside the filing of multiple patents. Developed in its Hong Kong-based R&D laboratories, these innovative vaccines target a broad spectrum of tumor antigens, immune checkpoint proteins, and other key components within the tumor-immune microenvironment.




Hashtag: #CKLifeSciences #CancerVaccines #R&D #BreastCancer #PatentApplication #Pharmaceutical

The issuer is solely responsible for the content of this announcement.

About CK Life Sciences

CK Life Sciences Int'l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences' operations are focused on conducting research and development into cancer vaccines and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit .

News from Asia

Prudential and Prudence Foundation Provide Free Mental Health Support to Vulnerable Communities

In partnership with Intellect, the programme will be launched in Malaysia and Vietnam to make mental healthcare more accessible for vulnerable or at-risk groups HONG KONG SAR - Media OutReach News...

Trend Micro Named a Leader in IDC MarketScape for CNAPP

HONG KONG SAR - Media OutReach Newswire - 2 July 2025 - Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybersecurity leader, today announced it has been named as a Leader in the IDC Ma...

Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha

HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025, Uni-Bio Science Group Limited (the "Group")grandly held a new medical aesthetics product launch event in Changsha, releasing the high-...

Amazon Singapore Unveils a Week of Prime Day Deals and a Special Public Maze Event for Prime Day 2025

Prime members can access exclusive deals from brands such as Neutrogena, FOREO, Resto, Cricut, Pigeon, PicassoTiles and Coca-Cola from 8 – 14 July. Free Public event: Amazon Prime Day Maze at Sun...

Themed Forum of "Mountain Biodiversity and Our Life" to Kick off "Guizhou Example" Empowering Global Mountain Eco-treatment

GUIYANG, CHINA - Media OutReach Newswire - 2 July 2025 - Recently, Eco Forum Global Guyang 2025 announced at a press briefing that the themed forum "Mountain Biodiversity and Our Life" will be hel...

Asia's First Porsche Design Tower Offers Revolutionary Luxury Living Experience to Bangkok's Vibrant Japanese Community

STUTTGART, GERMANY / TOKYO, JAPAN - Media OutReach Newswire - 24 June 2025 - Porsche Design Tower Bangkok emerges as a defining statement of excellence in luxury automotive-inspired living. As Asi...

Chubb Life Hong Kong Launches Chubb 1792 Club, a Prestigious Global Wealth Centre Designed to Elevate Customer Experience

HONG KONG SAR - Media OutReach Newswire - 16 June 2025 - Chubb Life Hong Kong (Chubb Life HK) today unveiled its first wealth centre, Chubb 1792 Club, marking a pivotal moment in its insurance and...

Cushman & Wakefield Greater China Wins Three Best Five-Star Awards at 2025 Asia Pacific Property Awards

HONG KONG SAR - Media OutReach Newswire - 19 June 2025 - Cushman & Wakefield, a leading global real estate services firm, has again been recognized at the Asia Pacific Property Awards, scoring...

Cushman & Wakefield and Corenet Global Release New Survey Results On "What Occupiers Want"

Cost remains king, but talent, flexibility, and service are reshaping real estate strategy globally HONG KONG SAR - Media OutReach Newswire - 2 July 2025 - Cushman & Wakefield (NYSE: CWK), in ...

Hong Kong banks showed moderate balance sheet growth amid global uncertainty in 2024, KPMG report finds

Disciplined cost management, risk vigilance, and digital innovation underpin sector resilience HONG KONG SAR - Media OutReach Newswire - 2 July 2025 – Hong Kong's banking sector demonstrated stead...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

Sell by LayBy